Moleculin shareholders approve reverse split authority, reject supermajority repeal

Moleculin Biotech, Inc. held its 2026 Annual Meeting of Stockholders on October 9, 2026, according to an 8-K filed with the SEC. As of August 19, 2026, the record date for the meeting, there were 19,477,380 shares of common stock outstanding and entitled to vote, with 8,247,089 shares present in person or by proxy constituting a quorum.¹

Shareholders elected five directors to the board: Walter V. Klemp, Robert E. George, Michael D. Cannon, John Climaco, and Elizabeth A. Cermak, each to serve until the next Annual Meeting of Stockholders.¹ Investors also ratified Grant Thornton, LLP as the company's independent registered public accounting firm for the year ending December 31, 2026.¹

On equity compensation, stockholders approved amendments to the company's 2024 Equity Plan, increasing the shares authorized for issuance by 3,861,894, bringing the total authorized under the plan to 3,875,999 shares.¹ A related non-binding advisory vote on executive compensation also passed.

Shareholders took up two charter amendments with differing outcomes. A proposal to eliminate supermajority voting requirements in the company's Amended and Restated Certificate of Incorporation failed, since it required the affirmative vote of two-thirds of outstanding shares.¹ However, stockholders approved an amendment granting the board authority to effect a reverse stock split at a ratio between 1-for-2 and 1-for-20, as determined by the board, prior to the one-year anniversary of the meeting.¹

Finally, shareholders authorized the adjournment of the meeting if necessary to solicit additional proxies for any proposals lacking sufficient votes.¹ The filing was signed by Chief Financial Officer Jonathan P. Foster on October 9, 2026.